A redox-related lncRNA prognostic signature (redox-LPS) consisting of four was developed and validated using 761 lung adenocarcinoma samples.
67 redox genes and 313 redox-related lncRNAs were identified in the analysis.
The redox-LPS demonstrated superior predictive capability for survival probability compared to three established models.
Risk score and stage were identified as independent prognostic indicators for lung adenocarcinoma.
A nomogram plot was created to predict survival probability based on risk score and stage, validated by calibration curves.
Differential cellular processes and signaling pathways were observed between high- and low-risk subgroups.
Simplified
Lung adenocarcinoma (LUAD) is one of the main causes of cancer deaths globally. Redox is emerging as a crucial contributor to the pathophysiology of LUAD, which can be regulated by (lncRNAs). The aim of our research is to identify a novel redox-related lncRNA prognostic signature (redox-LPS) for better prediction of LUAD prognosis. 535 LUAD samples from The Cancer Genome Atlas (TCGA) database and 226 LUAD samples from the Gene Expression Omnibus (GEO) database were included in our study. 67 redox genes and 313 redox-related lncRNAs were identified. After performing LASSO-Cox regression analysis, a redox-LPS consisting of four lncRNAs (i.e., CRNDE, CASC15, LINC01137, and CYP1B1-AS1) was developed and validated. Our redox-LPS was superior to another three established models in predicting survival probability of LUAD patients. Univariate and multivariate Cox regression analysis revealed that risk score and stage were independent prognostic indicators. A nomogram plot including risk score and stage was constructed to predict survival probability of LUAD patients; this was further verified by calibration curves. Functional enrichment analysis and gene set enrichment analysis, were performed to determine the differences in cellular processes and signaling pathways between the high - and low-risk subgroups. A variety of algorithms (such as single-sample gene set enrichment analysis and CIBERSOFT) were conducted to uncover the landscape of tumor immune microenvironment in the high- and low-risk subgroups. In conclusion, a novel independent redox-LPS was constructed and validated for LUAD patients, which might provide new insights for clinical decision-making and precision medicine.
Key numbers
535 samples
Cohort Size
Total LUAD samples from TCGA database used for analysis.
2
Independent Prognostic Indicators
Risk score and stage identified as independent prognostic factors.
0.779
AUC for One-Year Survival
AUC value for the redox-LPS in predicting one-year survival in the train cohort.
Full Text
We can’t show the full text here under this license.
